Nephrogenex Inc (NRX) 0.14 $NRX
NephroGenex, Inc. Commences Voluntary Chapter 11 Proceeding; Seeks To Initiate Sale Process Under Section 363
BusinessWire - Mon May 02, 7:00AM CDT
NephroGenex, Inc. (Nasdaq:NRX), a pharmaceutical company focused on the development of therapeutics to treat kidney disease, today announced that it filed a voluntary petition under Chapter 11 of the United States Bankruptcy Code in the United States Bankruptcy Court for the District of Delaware (the "Court"
.
NRX: 0.14 (+0.01)
NephroGenex to Present at the 18th Annual BIO CEO & Investor Conference
BusinessWire - Wed Jan 27, 7:00AM CST
NephroGenex, Inc. (Nasdaq:NRX), a pharmaceutical company focused on the development of therapeutics to treat kidney disease, today announced that CEO and President Pierre Legault will present a corporate overview of the Company and meet with investors at the 18th Annual BIO CEO & Investor Conference. The presentation will take place on Monday, February 8 at 3:00 pm EST at The Waldorf Astoria in New York City.
NRX: 0.14 (+0.01)
NephroGenex to Participate in Two Healthcare Conferences in January
BusinessWire - Wed Jan 06, 7:00AM CST
NephroGenex, Inc. (Nasdaq:NRX), a pharmaceutical company focused on the development of therapeutics to treat kidney disease, today announced that CEO and President Pierre Legault will present a corporate overview of the Company at two upcoming healthcare conferences in January. The Company will also meet with members of the investment community while in San Francisco during the week of January 11.
NRX: 0.14 (+0.01)
NephroGenex Announces Formation of Scientific Advisory Board
BusinessWire - Tue Jan 05, 7:00AM CST
NephroGenex, Inc. (Nasdaq:NRX), a pharmaceutical company focused on the development of therapeutics to treat kidney disease, today announced the appointment of leading experts in nephrology to its newly formed Scientific Advisory Board (SAB). The SAB will serve as a strategic resource to NephroGenex as it continues to develop the Company's novel drug candidates to treat kidney disease.
NRX: 0.14 (+0.01)
The Road Ahead - New Reports on NephroGenex, FairPoint Communications, Avalanche Biotechnologies and Exar
ACCESSWIRE - Wed Dec 16, 7:01AM CST
NEW YORK, NY / ACCESSWIRE / December 16, 2015 / Moments ago, Trader's Choice released new research updates concerning several important developing situations including the following equities: NephroGenex Inc. (NASDAQ: NRX), FairPoint Communications Inc. (NASDAQ: FRP), Avalanche Biotechnologies Inc. (NASDAQ: AAVL) and Exar Corp. (NYSE: EXAR). Trader's Choice has perfected the profitable art of picking stocks, cutting through the noise to deliver the top trade, every year. The full Research Packages are being made available to the public on a complimentary basis.
FRP: 15.26 (+0.29), NRX: 0.14 (+0.01), AAVL: 4.14 (-0.18), EXAR: 8.15 (+0.15)
NephroGenex awarded US FDA clearance of IND application for clinical study of intravenous pyridorin for acute kidney injury
M2 - Tue Dec 15, 4:10AM CST
Pharmaceutical company NephroGenex (Nasdaq:NRX) revealed on Monday the receipt of approval from the US Food and Drug Administration for its Investigational New Drug (IND) application for clinical studies with intravenous Pyridorin for the treatment of acute kidney injury.
NRX: 0.14 (+0.01)
4 Stocks to Watch Trading Under $500M Market Cap
ACCESSWIRE - Mon Dec 14, 9:27AM CST
NEW YORK, NY / ACCESSWIRE / December 14, 2015 / MomentumStockAlert.com is a newsletter alert service that focuses on companies on the NASDAQ & NYSE. We only highlight quality companies with big potential. This commitment provides our subscribers with only the best recommendations of companies for short and long-term investments. Receive our free trade alerts via text message (SMS) and/or email at http://www.MomentumStockAlert.com. Today we are focusing on four companies to watch that have been attracting the attention of major investors.
AVXL: 4.27 (+0.12), NRX: 0.14 (+0.01), AKBA: 7.79 (+0.46), BSI: 3.19 (unch)
NephroGenex Announces FDA Clearance of IND Application for Clinical Study of Intravenous Pyridorin in the Treatment of Acute Kidney Injury
BusinessWire - Mon Dec 14, 7:00AM CST
NephroGenex, Inc. (Nasdaq:NRX), a pharmaceutical company focused on the development of therapeutics to treat kidney disease, today announced that the U.S. Food and Drug Administration has cleared the Company's Investigational New Drug (IND) application for clinical studies with intravenous Pyridorin(R) for the treatment of acute kidney injury.
NRX: 0.14 (+0.01)
NephroGenex Reports Third Quarter 2015 Financial Results
BusinessWire - Wed Nov 11, 3:05PM CST
NephroGenex, Inc. (Nasdaq:NRX), a pharmaceutical company focused on the development of therapeutics to treat kidney disease, today reported financial results and business highlights for the third quarter ended September 30, 2015.
NRX: 0.14 (+0.01)
NephroGenex to Host Conference Call and Webcast on Third Quarter 2015 Financial Results on Thursday, November 12, 2015
BusinessWire - Wed Nov 04, 7:00AM CST
NephroGenex, Inc. (Nasdaq: NRX), a pharmaceutical company focused on the development of therapeutics to treat kidney disease, will report financial results for the quarter ended September 30, 2015 on Wednesday, November 11, after the U.S. financial markets close. The Company will host a conference call and webcast the following day, Thursday, November 12, at 8:30 a.m. EST, to review third quarter results and provide an update on its PIONEER program for diabetic nephropathy and upcoming milestones.
NRX: 0.14 (+0.01)
NephroGenex Announces $5.5 Million Private Placement
BusinessWire - Tue Nov 03, 10:26AM CST
NephroGenex, Inc. (Nasdaq:NRX), a pharmaceutical company focused on the development of therapeutics to treat kidney disease, today announced it has entered into a definitive agreement to sell securities to healthcare dedicated and institutional investors in a private placement for aggregate gross proceeds of approximately $5.5 million before deducting offering expenses payable by the Company. The closing of the offering is expected to occur on or about November 6, 2015 and is subject to satisfaction of customary closing conditions.
NRX: 0.14 (+0.01)
NephroGenex to Present at the 2015 Aegis Growth Conference
BusinessWire - Wed Sep 30, 7:00AM CDT
NephroGenex, Inc. (Nasdaq:NRX), a pharmaceutical company focused on the development of therapeutics to treat kidney disease, today announced that Chief Executive Officer Pierre Legault will present a corporate overview of the Company and meet with investors at the 2015 Aegis Growth Conference in Las Vegas. The presentation will take place on Thursday, October 8 at 10:00 am PDT at The Encore at Wynn hotel.
NRX: 0.14 (+0.01)
NephroGenex Reports Second Quarter 2015 Financial Results
BusinessWire - Wed Aug 12, 3:12PM CDT
NephroGenex, Inc. (Nasdaq:NRX), a pharmaceutical company focused on the development of therapeutics to treat kidney disease, today reported financial results and business highlights for the second quarter ended June 30, 2015.
NRX: 0.14 (+0.01)
NephroGenex To Host Conference Call and Webcast on Second Quarter 2015 Financial Results on Thursday, August 13, 2015
BusinessWire - Thu Aug 06, 3:09PM CDT
NephroGenex, Inc. (Nasdaq:NRX), a pharmaceutical company focused on the development of therapeutics to treat kidney disease, will report financial results for the quarter ended June 30, 2015 on Wednesday, August 12, after the U.S. financial markets close. The Company will host a conference call and webcast the following day, Thursday, August 13, at 8 a.m. Eastern, to review second quarter results and provide an update on its PIONEER program for diabetic nephropathy and upcoming milestones.
NRX: 0.14 (+0.01)
NephroGenex elects Dr Jaikrishna Patel as CMO
M2 - Tue Jul 28, 5:48AM CDT
Pharmaceutical company NephroGenex (Nasdaq:NRX) revealed on Monday that it has appointed Dr Jaikrishna Patel as its chief medical officer.
NRX: 0.14 (+0.01)
NephroGenex Appoints Dr. Jaikrishna Patel as Chief Medical Officer
BusinessWire - Mon Jul 27, 7:00AM CDT
NephroGenex, Inc. (Nasdaq:NRX), a pharmaceutical company focused on the development of therapeutics to treat kidney disease, today announced the appointment of Dr. Jaikrishna Patel to the position of Chief Medical Officer. Dr. Patel will help guide the Company's Phase 3 PIONEER program with oral Pyridorin(R) for the treatment of diabetic nephropathy, and the development of an intravenous formulation of Pyridorin for acute kidney injury.
NRX: 0.14 (+0.01)
NephroGenex concludes public offering at exercise price of USD6.25 per share
M2 - Thu Jul 23, 4:35AM CDT
Pharmaceutical company NephroGenex (Nasdaq:NRX) revealed on Wednesday that it has completed its public offering of of common stock and warrants at an exercise price of USD6.25 per share.
NRX: 0.14 (+0.01)
NephroGenex, Inc. Announces Closing of Public Offering of Common Stock and Warrants
BusinessWire - Wed Jul 22, 3:05PM CDT
NephroGenex, Inc. (Nasdaq:NRX), a pharmaceutical company focused on the development of therapeutics to treat kidney disease, today announced the closing of its previously announced underwritten public offering of 1,500,000 shares of common stock, and warrants to purchase an aggregate of 1,500,000 shares of common stock at an exercise price of $6.25 per share. The underwriters also exercised their over-allotment option to purchase warrants to purchase an aggregate of 225,000 shares of common stock. The warrants are immediately exercisable and expire on July 22, 2020. The shares of common stock and warrants are immediately separable and will be issued separately.
NRX: 0.14 (+0.01)
NephroGenex, Inc. Prices $7,500,000 Public Offering
BusinessWire - Thu Jul 16, 4:38PM CDT
NephroGenex, Inc. (Nasdaq:NRX), a pharmaceutical company focused on the development of therapeutics to treat kidney disease, today announced the pricing of an underwritten public offering of 1,500,000 shares of its common stock and warrants to purchase up to an aggregate of 1,500,000 shares of its common stock at a combined offering price of $5.00 per share and accompanying warrant. The warrants will have a per share exercise price of $6.25, are exercisable immediately and will expire five years from the date of issuance. The gross proceeds to NephroGenex from this offering are expected to be approximately $7,500,000, before deducting underwriting discounts and commissions and other estimated offering expenses. NephroGenex intends to use the net proceeds from the offering for working capital and general corporate purposes. NephroGenex has granted the underwriters a 45-day option to purchase up to an additional 225,000 shares of common stock and/or 225,000 additional warrants to cover over-allotments, if any. The offering is expected to close on July 22, 2015, subject to customary closing conditions.
NRX: 0.14 (+0.01)
NephroGenex to Participate in Two Healthcare Conferences in June
BusinessWire - Thu Jun 04, 7:00AM CDT
NephroGenex, Inc. (Nasdaq: NRX), a pharmaceutical company focused on the development of therapeutics to treat kidney disease, today announced that Chief Executive Officer Pierre Legault will present a corporate overview of the Company and meet with members of the investment community at two healthcare conferences in June.
NRX: 0.14 (+0.01)
NephroGenex, Inc. Commences Voluntary Chapter 11 Proceeding; Seeks To Initiate Sale Process Under Section 363
BusinessWire - Mon May 02, 7:00AM CDT
NephroGenex, Inc. (Nasdaq:NRX), a pharmaceutical company focused on the development of therapeutics to treat kidney disease, today announced that it filed a voluntary petition under Chapter 11 of the United States Bankruptcy Code in the United States Bankruptcy Court for the District of Delaware (the "Court"
. NRX: 0.14 (+0.01)
NephroGenex to Present at the 18th Annual BIO CEO & Investor Conference
BusinessWire - Wed Jan 27, 7:00AM CST
NephroGenex, Inc. (Nasdaq:NRX), a pharmaceutical company focused on the development of therapeutics to treat kidney disease, today announced that CEO and President Pierre Legault will present a corporate overview of the Company and meet with investors at the 18th Annual BIO CEO & Investor Conference. The presentation will take place on Monday, February 8 at 3:00 pm EST at The Waldorf Astoria in New York City.
NRX: 0.14 (+0.01)
NephroGenex to Participate in Two Healthcare Conferences in January
BusinessWire - Wed Jan 06, 7:00AM CST
NephroGenex, Inc. (Nasdaq:NRX), a pharmaceutical company focused on the development of therapeutics to treat kidney disease, today announced that CEO and President Pierre Legault will present a corporate overview of the Company at two upcoming healthcare conferences in January. The Company will also meet with members of the investment community while in San Francisco during the week of January 11.
NRX: 0.14 (+0.01)
NephroGenex Announces Formation of Scientific Advisory Board
BusinessWire - Tue Jan 05, 7:00AM CST
NephroGenex, Inc. (Nasdaq:NRX), a pharmaceutical company focused on the development of therapeutics to treat kidney disease, today announced the appointment of leading experts in nephrology to its newly formed Scientific Advisory Board (SAB). The SAB will serve as a strategic resource to NephroGenex as it continues to develop the Company's novel drug candidates to treat kidney disease.
NRX: 0.14 (+0.01)
The Road Ahead - New Reports on NephroGenex, FairPoint Communications, Avalanche Biotechnologies and Exar
ACCESSWIRE - Wed Dec 16, 7:01AM CST
NEW YORK, NY / ACCESSWIRE / December 16, 2015 / Moments ago, Trader's Choice released new research updates concerning several important developing situations including the following equities: NephroGenex Inc. (NASDAQ: NRX), FairPoint Communications Inc. (NASDAQ: FRP), Avalanche Biotechnologies Inc. (NASDAQ: AAVL) and Exar Corp. (NYSE: EXAR). Trader's Choice has perfected the profitable art of picking stocks, cutting through the noise to deliver the top trade, every year. The full Research Packages are being made available to the public on a complimentary basis.
FRP: 15.26 (+0.29), NRX: 0.14 (+0.01), AAVL: 4.14 (-0.18), EXAR: 8.15 (+0.15)
NephroGenex awarded US FDA clearance of IND application for clinical study of intravenous pyridorin for acute kidney injury
M2 - Tue Dec 15, 4:10AM CST
Pharmaceutical company NephroGenex (Nasdaq:NRX) revealed on Monday the receipt of approval from the US Food and Drug Administration for its Investigational New Drug (IND) application for clinical studies with intravenous Pyridorin for the treatment of acute kidney injury.
NRX: 0.14 (+0.01)
4 Stocks to Watch Trading Under $500M Market Cap
ACCESSWIRE - Mon Dec 14, 9:27AM CST
NEW YORK, NY / ACCESSWIRE / December 14, 2015 / MomentumStockAlert.com is a newsletter alert service that focuses on companies on the NASDAQ & NYSE. We only highlight quality companies with big potential. This commitment provides our subscribers with only the best recommendations of companies for short and long-term investments. Receive our free trade alerts via text message (SMS) and/or email at http://www.MomentumStockAlert.com. Today we are focusing on four companies to watch that have been attracting the attention of major investors.
AVXL: 4.27 (+0.12), NRX: 0.14 (+0.01), AKBA: 7.79 (+0.46), BSI: 3.19 (unch)
NephroGenex Announces FDA Clearance of IND Application for Clinical Study of Intravenous Pyridorin in the Treatment of Acute Kidney Injury
BusinessWire - Mon Dec 14, 7:00AM CST
NephroGenex, Inc. (Nasdaq:NRX), a pharmaceutical company focused on the development of therapeutics to treat kidney disease, today announced that the U.S. Food and Drug Administration has cleared the Company's Investigational New Drug (IND) application for clinical studies with intravenous Pyridorin(R) for the treatment of acute kidney injury.
NRX: 0.14 (+0.01)
NephroGenex Reports Third Quarter 2015 Financial Results
BusinessWire - Wed Nov 11, 3:05PM CST
NephroGenex, Inc. (Nasdaq:NRX), a pharmaceutical company focused on the development of therapeutics to treat kidney disease, today reported financial results and business highlights for the third quarter ended September 30, 2015.
NRX: 0.14 (+0.01)
NephroGenex to Host Conference Call and Webcast on Third Quarter 2015 Financial Results on Thursday, November 12, 2015
BusinessWire - Wed Nov 04, 7:00AM CST
NephroGenex, Inc. (Nasdaq: NRX), a pharmaceutical company focused on the development of therapeutics to treat kidney disease, will report financial results for the quarter ended September 30, 2015 on Wednesday, November 11, after the U.S. financial markets close. The Company will host a conference call and webcast the following day, Thursday, November 12, at 8:30 a.m. EST, to review third quarter results and provide an update on its PIONEER program for diabetic nephropathy and upcoming milestones.
NRX: 0.14 (+0.01)
NephroGenex Announces $5.5 Million Private Placement
BusinessWire - Tue Nov 03, 10:26AM CST
NephroGenex, Inc. (Nasdaq:NRX), a pharmaceutical company focused on the development of therapeutics to treat kidney disease, today announced it has entered into a definitive agreement to sell securities to healthcare dedicated and institutional investors in a private placement for aggregate gross proceeds of approximately $5.5 million before deducting offering expenses payable by the Company. The closing of the offering is expected to occur on or about November 6, 2015 and is subject to satisfaction of customary closing conditions.
NRX: 0.14 (+0.01)
NephroGenex to Present at the 2015 Aegis Growth Conference
BusinessWire - Wed Sep 30, 7:00AM CDT
NephroGenex, Inc. (Nasdaq:NRX), a pharmaceutical company focused on the development of therapeutics to treat kidney disease, today announced that Chief Executive Officer Pierre Legault will present a corporate overview of the Company and meet with investors at the 2015 Aegis Growth Conference in Las Vegas. The presentation will take place on Thursday, October 8 at 10:00 am PDT at The Encore at Wynn hotel.
NRX: 0.14 (+0.01)
NephroGenex Reports Second Quarter 2015 Financial Results
BusinessWire - Wed Aug 12, 3:12PM CDT
NephroGenex, Inc. (Nasdaq:NRX), a pharmaceutical company focused on the development of therapeutics to treat kidney disease, today reported financial results and business highlights for the second quarter ended June 30, 2015.
NRX: 0.14 (+0.01)
NephroGenex To Host Conference Call and Webcast on Second Quarter 2015 Financial Results on Thursday, August 13, 2015
BusinessWire - Thu Aug 06, 3:09PM CDT
NephroGenex, Inc. (Nasdaq:NRX), a pharmaceutical company focused on the development of therapeutics to treat kidney disease, will report financial results for the quarter ended June 30, 2015 on Wednesday, August 12, after the U.S. financial markets close. The Company will host a conference call and webcast the following day, Thursday, August 13, at 8 a.m. Eastern, to review second quarter results and provide an update on its PIONEER program for diabetic nephropathy and upcoming milestones.
NRX: 0.14 (+0.01)
NephroGenex elects Dr Jaikrishna Patel as CMO
M2 - Tue Jul 28, 5:48AM CDT
Pharmaceutical company NephroGenex (Nasdaq:NRX) revealed on Monday that it has appointed Dr Jaikrishna Patel as its chief medical officer.
NRX: 0.14 (+0.01)
NephroGenex Appoints Dr. Jaikrishna Patel as Chief Medical Officer
BusinessWire - Mon Jul 27, 7:00AM CDT
NephroGenex, Inc. (Nasdaq:NRX), a pharmaceutical company focused on the development of therapeutics to treat kidney disease, today announced the appointment of Dr. Jaikrishna Patel to the position of Chief Medical Officer. Dr. Patel will help guide the Company's Phase 3 PIONEER program with oral Pyridorin(R) for the treatment of diabetic nephropathy, and the development of an intravenous formulation of Pyridorin for acute kidney injury.
NRX: 0.14 (+0.01)
NephroGenex concludes public offering at exercise price of USD6.25 per share
M2 - Thu Jul 23, 4:35AM CDT
Pharmaceutical company NephroGenex (Nasdaq:NRX) revealed on Wednesday that it has completed its public offering of of common stock and warrants at an exercise price of USD6.25 per share.
NRX: 0.14 (+0.01)
NephroGenex, Inc. Announces Closing of Public Offering of Common Stock and Warrants
BusinessWire - Wed Jul 22, 3:05PM CDT
NephroGenex, Inc. (Nasdaq:NRX), a pharmaceutical company focused on the development of therapeutics to treat kidney disease, today announced the closing of its previously announced underwritten public offering of 1,500,000 shares of common stock, and warrants to purchase an aggregate of 1,500,000 shares of common stock at an exercise price of $6.25 per share. The underwriters also exercised their over-allotment option to purchase warrants to purchase an aggregate of 225,000 shares of common stock. The warrants are immediately exercisable and expire on July 22, 2020. The shares of common stock and warrants are immediately separable and will be issued separately.
NRX: 0.14 (+0.01)
NephroGenex, Inc. Prices $7,500,000 Public Offering
BusinessWire - Thu Jul 16, 4:38PM CDT
NephroGenex, Inc. (Nasdaq:NRX), a pharmaceutical company focused on the development of therapeutics to treat kidney disease, today announced the pricing of an underwritten public offering of 1,500,000 shares of its common stock and warrants to purchase up to an aggregate of 1,500,000 shares of its common stock at a combined offering price of $5.00 per share and accompanying warrant. The warrants will have a per share exercise price of $6.25, are exercisable immediately and will expire five years from the date of issuance. The gross proceeds to NephroGenex from this offering are expected to be approximately $7,500,000, before deducting underwriting discounts and commissions and other estimated offering expenses. NephroGenex intends to use the net proceeds from the offering for working capital and general corporate purposes. NephroGenex has granted the underwriters a 45-day option to purchase up to an additional 225,000 shares of common stock and/or 225,000 additional warrants to cover over-allotments, if any. The offering is expected to close on July 22, 2015, subject to customary closing conditions.
NRX: 0.14 (+0.01)
NephroGenex to Participate in Two Healthcare Conferences in June
BusinessWire - Thu Jun 04, 7:00AM CDT
NephroGenex, Inc. (Nasdaq: NRX), a pharmaceutical company focused on the development of therapeutics to treat kidney disease, today announced that Chief Executive Officer Pierre Legault will present a corporate overview of the Company and meet with members of the investment community at two healthcare conferences in June.
NRX: 0.14 (+0.01)
